Pregled prema Autor
Herbst, Roy S
Prikaz rezultata 1 do 5 od 5
| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
| 2020 | Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC | Herbst, Roy S; ...; Andric, Zoran G   ; ...; (broj, koautora 22) | Naučni članak | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
| 2020 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 21) | Konferencijski rad | |
| 2019 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Konferencijski rad | |
| 2020 | Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Konferencijski rad | |
| 2021 | IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Konferencijski rad | |